© 2022 MJH Life Sciences and Modern Retina. All rights reserved.
© 2022 MJH Life Sciences™ and Modern Retina. All rights reserved.
June 30, 2022
Dilsher Dhoot, MD, discusses the post hoc analysis of the Copernicus and Galileo trials, which investigated if a delay in treatment would affect visual acuity gains or change in anatomy.
June 29, 2022
According to the company, the primary outcome of the MGT009 study is safety, and botaretigene sparoparvovec treatment was found to be generally safe and well-tolerated.
June 28, 2022
Richard Rosen, MD, shares insights on how imaging can capture hyalocytes and their movement without the use of dyes.
June 27, 2022
Survey respondents point to a perceived gap in treatments for uveitic macular edema, document interest in suprachoroidal drug delivery.
June 26, 2022
LumiThera Inc. noted that the trial results demonstrated statistically significant improvement in the prespecified primary endpoint in BCVA at 13 months in the PBM treatment group over the sham-treatment group.
June 25, 2022
A team led by researchers from the University of Geneva has identified a molecular mechanism that causes degeneration of the eye’s photoreceptors, which can lead to blindness.
June 24, 2022
An end-of-week review of retina news and stories from June 18 to June 24.
June 23, 2022
Steven Yeh, MD, provides a brief overview of available therapies for noninfectious uveitis and uveitis macular edema.
David Boyer, MD, discusses the Phase 3 investigation for OPT-302 combination therapy for wet AMD.
June 21, 2022
A study by Orbis International found that children with myopia experienced significantly higher levels of depression and anxiety than their peers without vision impairment.